X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs MYLAN (US) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   MYLAN
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
MYLAN
Dec-14
FRESENIUS KABI ONCO./
MYLAN
5-Yr Chart
Click to enlarge
High Rs1764,254-   
Low Rs792,998-   
Sales per share (Unadj.) Rs37.71,456.2-  
Earnings per share (Unadj.) Rs5.1175.4-  
Cash flow per share (Unadj.) Rs6.7282.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5723.9-  
Shares outstanding (eoy) m158.23378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.42.5 135.6%   
Avg P/E ratio x25.020.7 120.9%  
P/CF ratio (eoy) x18.912.8 147.4%  
Price / Book Value ratio x3.05.0 59.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,371,817 1.5%   
No. of employees `0001.225.0 4.6%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.222,039.1 23.5%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.62,655.0 26.3%   
INCOME DATA
Net Sales Rs m5,963550,976 1.1%  
Other income Rs m18-3,212 -0.6%   
Total revenues Rs m5,981547,765 1.1%   
Gross profit Rs m1,430137,030 1.0%  
Depreciation Rs m25840,467 0.6%   
Interest Rs m-2623,766 -0.1%   
Profit before tax Rs m1,21669,586 1.7%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,926 11.7%   
Profit after tax Rs m80666,374 1.2%  
Gross profit margin %24.024.9 96.4%  
Effective tax rate %28.14.2 669.1%   
Net profit margin %13.512.0 112.2%  
BALANCE SHEET DATA
Current assets Rs m5,102484,381 1.1%   
Current liabilities Rs m2,385378,689 0.6%   
Net working cap to sales %45.619.2 237.5%  
Current ratio x2.11.3 167.2%  
Inventory Days Days15078 192.2%  
Debtors Days Days113107 105.6%  
Net fixed assets Rs m5,148127,467 4.0%   
Share capital Rs m15819,484 0.8%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,732273,890 2.5%   
Long term debt Rs m952409,164 0.2%   
Total assets Rs m10,3881,103,202 0.9%  
Interest coverage x-45.83.9 -1,165.4%   
Debt to equity ratio x0.11.5 9.5%  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %7.58.2 91.9%  
Return on equity %12.024.2 49.4%  
Return on capital %14.613.6 107.2%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,27472,426 1.8%  
From Investments Rs m-1,204-57,117 2.1%  
From Financial Activity Rs m-196-19,084 1.0%  
Net Cashflow Rs m-126-3,775 3.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare FRESENIUS KABI ONCO. With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: FDC LTD.  AUROBINDO PHARMA  WOCKHARDT LTD.  DISHMAN PHARMA  IPCA LABS  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS